Cargando…
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
Autores principales: | McKenna, Avery, Lin, Grace A, Whittington, Melanie D, Nikitin, Dmitriy, Herron-Smith, Serina, Campbell, Jonathan D, Agboola, Foluso, Pearson, Steven D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387920/ https://www.ncbi.nlm.nih.gov/pubmed/37404068 http://dx.doi.org/10.18553/jmcp.2023.29.7.857 |
Ejemplares similares
-
The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2022) -
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2022) -
The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021) -
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2022) -
The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)